Nautilus Biotechnology (NAUT) Retained Earnings (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Retained Earnings of $492.6 million for Q2 2026, little changed sequentially from $491.2 million in Q1 2026, and up 1.43% YoY from $485.7 million in Q2 2025.
Nautilus Biotechnology (NAUT) Retained Earnings (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Retained Earnings for 7 years, with the latest figure at $492.6 million in Q2 2026.
- Quarterly Retained Earnings rose 1.43% year-over-year to $492.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $492.6 million (up 1.43% YoY) and the FY2025 annual result came in at $488.7 million, up 1.47% from the prior year.
- Retained Earnings held at $492.6 million in Q2 2026 per NAUT's latest filing, from $491.2 million in the prior quarter.
- Over five years, Retained Earnings peaked at $492.6 million in Q2 2026 and troughed at $446.7 million in Q1 2022.
- A 5-year average of $471.7 million and a median of $473.0 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2026: Retained Earnings surged 6025.63% in 2022, then increased 1.43% in 2026.
- Over 5 years, Retained Earnings stood at $455.3 million in 2022, then increased by 2.75% to $467.8 million in 2023, then rose by 2.96% to $481.7 million in 2024, then grew by 1.47% to $488.7 million in 2025, then rose by 0.79% to $492.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $492.6 million, $491.2 million, and $488.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 4.38 Bn |
| 10 | Nautilus Biotechnology | 120.07 Mn | 120.07 Mn | 175,000.00 | 492.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 492.62 Mn |
| Mar 31, 2026 | 491.21 Mn |
| Dec 31, 2025 | 488.74 Mn |
| Sep 30, 2025 | 487.17 Mn |
| Jun 30, 2025 | 485.67 Mn |
| Mar 31, 2025 | 483.87 Mn |
| Dec 31, 2024 | 481.68 Mn |
| Sep 30, 2024 | 478.12 Mn |
| Jun 30, 2024 | 474.79 Mn |
| Mar 31, 2024 | 471.19 Mn |
| Dec 31, 2023 | 467.83 Mn |
| Sep 30, 2023 | 464.51 Mn |
| Jun 30, 2023 | 461.39 Mn |
| Mar 31, 2023 | 458.19 Mn |
| Dec 31, 2022 | 455.33 Mn |
| Sep 30, 2022 | 452.36 Mn |
| Jun 30, 2022 | 449.41 Mn |
| Mar 31, 2022 | 446.65 Mn |
| Dec 31, 2021 | 444.39 Mn |
| Sep 30, 2021 | 441.80 Mn |